Solventum Corporation Q3 2026 Earnings Recap

Solventum rose 3.7% after earnings, as management reported Q3 organic growth and EPS above its plan despite the ERP cutover. The reaction appears to reflect confidence in execution and the separation milestone, though the call did not provide specific growth or EPS figures.

Key Takeaways

• Management said all key financial metrics were in line with or ahead of expectations, with organic growth and EPS above plan; results included the reversal of advanced orders from the prior quarter.
• The Americas ERP cutover is complete, and separation is now more than 90% complete. Management said separation costs rolling off should strengthen Q4 free cash flow.
• A renegotiated long-term raw-material supply agreement with 3M supports supply continuity and is cited as a factor in improving year-over-year margins in 2027; management also noted the comparison will include a 2026 one-time tariff refund.
• Solventum is evaluating both sale and spin options for Health Information Systems. Proceeds would primarily go toward paying down debt and returning capital to shareholders.
• Management highlighted a large wound-care opportunity: V.A.C. therapy is used about 10% of the time, and studies cited on the call show wounds are ready for closure almost twice as fast and amputations are reduced 60% versus non-V.A.C. treatments.